WINNIPEG, Manitoba (August 19, 2009) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company has been selected to present at the Partners in Biomedical Defence 2009 Conference on September 15, 2009 in Washington, DC. This event will bring together the leading innovative Canadian companies and researchers involved in biomedical defense research and development of therapeutics and vaccines with many U.S. government agencies.
“This formal bilateral meeting organized by the Canadian Embassy in Washington, DC is the first of its kind and a great opportunity for Kane Biotech to directly interact with the key U.S. government agencies and decision makers”, stated Gord Froehlich, President and CEO of Kane Biotech.
The U.S. government agencies scheduled to attend the bilateral meeting include: The Biomedical Advanced Research & Development Authority (BARDA), Walter Reed Army Institute of Research (WRAIR), Food and Drug Administration (FDA), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Health and Human Services (HHS), United States Army Medical Research Institute of Infectious Diseases and the Defense Threat Reduction Agency (DTRA).
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
For more information, please contact:
Gord Froehlich
President & Chief Executive Officer
Kane Biotech Inc.
204-477-7592 phone
204-453-1314 fax
ir@kanebiotech.com
www.kanebiotech.com